Provectus announces acceptance of PV-10 abstract for SIR annual meeting
Provectus announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 as a single-agent for the treatment of primary or metastatic tumors of the liver will be presented at the upcoming Society of Interventional Radiology 2020 Annual Scientific Meeting, to be held March 28-April 2, 2020, in Seattle, Washington. The accepted abstract is: "Oncolytic immunotherapy of hepatic tumors with intralesional rose bengal disodium." PV-10 is administered percutaneously when targeting primary or metastatic tumors of the liver, such as hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and metastatic uveal melanoma. Intralesional injection with PV-10 can yield immunogenic cell death in solid tumor cancers that results in tumor-specific reactivity in circulating T cells.